Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, ZG-001, intended to treat adults with major depressive disorder with acute suicidal ideation or behavior (MDSI).
ZG-001’s Mechanism and Pre-Clinical Efficacy
ZG-001 is under development to address various forms of adult depressive disorder, including MDSI, treatment-resistant depression (TRD), and major depressive disorder (MDD). Pre-clinical studies have demonstrated a clear antidepressant mechanism for ZG-001. A single oral administration can rapidly increase the expression of pTrkB in the brain, activate the BDNF-TrkB signaling pathway, and thus provide a rapid and long-lasting antidepressant effect. ZG-001 has shown good antidepressant activity in multiple classic animal models, marked by a rapid onset and enduring efficacy. Additionally, ZG-001 has exhibited excellent metabolic properties and safety.- Flcube.com
